When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Medicare announces weight-loss drugs, including Ozempic ... - AOL

   www.aol.com/medicare-announces-15-drugs-price...

   The drugs have faced public backlash over their high price, fueling demand for cheaper alternatives. ... Trelegy Ellipta, an asthma treatment. Xtandi, for prostate cancer. Pomalyst, a chemotherapy ...

3. Medicare targets popular weight loss drugs Ozempic, Wegovy ...

   www.aol.com/medicare-targets-popular-weight-loss...

   The asthma and chronic obstructive pulmonary disease Trelegy Ellipta accounted for $5.1 billion in spending. Under President Joe Biden's 2022 climate and health legislation, ...

4. Ozempic and Wegovy selected for next round of Medicare drug ...

   www.aol.com/ozempic-wegovy-selected-next-round...

   Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden ...

5. Fluticasone furoate/umeclidinium bromide/vilanterol - Wikipedia

   en.wikipedia.org/wiki/Fluticasone_furoate/...

   The combination fluticasone furoate/umeclidinium bromide/vilanterol product is approved by the US Food and Drug Administration with an indication for the maintenance treatment of a chronic lung problem called chronic obstructive pulmonary disease (COPD) in adults who (1) have already tried fluticasone furoate/vilanterol (brand name Breo Ellipta) but are still experiencing symptoms of airway ...

6. Umeclidinium bromide - Wikipedia

   en.wikipedia.org/wiki/Umeclidinium_bromide

   Umeclidinium bromide, sold under the brand name Incruse Ellipta, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). [3] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol ) [ 4 ] [ 5 ] and also as a triple-therapy ...

7. Vilanterol - Wikipedia

   en.wikipedia.org/wiki/Vilanterol

   Vilanterol is an ultra-long-acting β 2-adrenoceptor agonist which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD). [1] [2] The combination is also approved for the treatment of asthma in Canada, Europe, Japan [3] and ...